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ABSTRACT 
Cellular senescence is a widespread stress response and is widely considered to be an 
alternative cancer therapeutic goal. Unlike apoptosis, senescence is composed of a 
diverse set of sub-phenotypes; depending on which of its associated effector programs 
are engaged. Here we establish a simple and sensitive, cell-based, pro-senescence 
screen with detailed validation assays. We have characterized the screen using a focused 
tool compound kinase inhibitor library. We have identified a series of compounds that 
induce different types of senescence, including a unique phenotype associated with 
irregularly shaped nuclei and the progressive accumulation of pseudo-G1 tetraploidy in 
human diploid fibroblasts. Downstream analyses showed that all those compounds that 
induced tetraploid senescence, inhibited Aurora kinase B (AURKB). AURKB is the 
catalytic component of the chromosome passenger complex, which is involved in 
correct chromosome alignment and segregation, the spindle assembly checkpoint (SAC), 
and cytokinesis. Although aberrant mitosis and senescence have been linked, a specific 
characterization of AURKB in the context of senescence is still required. This proof-of-
principle study suggests that our protocol is capable of amplifying tetraploid senescence, 
which can be observed only in a small population of oncogenic RAS-induced 
senescence, and provides additional justification for AURKB as a cancer therapeutic 
target.  
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INTRODUCTION 
Cellular senescence is a state of stable or ‘irreversible’ cell cycle arrest induced by 
various cytotoxic factors, including telomere dysfunction, DNA damage, oxidative 
stress, oncogenic stress, and some type of cytokines (Correia-Melo et al., 2014; Salama 
et al., 2014) Although senescence was originally defined in normal human diploid 
fibroblasts (HDFs), the best-characterized culture model of senescence, a similar 
phenotype can be induced in a wide range of cell types as well as in in vivo contexts that 
are associated with various pathophysiological contexts, such as tumorigenesis (Pérez-
Mancera et al., 2014), tissue repair (Krizhanovsky et al., 2008; Jun and Lau, 2010), 
ageing (López-Otín et al., 2013), and more recently embryogenesis (Chuprin et al., 
2013; Muñoz-Espín et al., 2013; Storer et al., 2013). Among all these, oncogene-
induced senescence (OIS), where excessive mitogenic stress provokes senescence 
effectors leading to progressive development of senescence phenotypes in culture and 
animal models, underscores the tumour suppressor role of senescence. In addition, it has 
been shown that senescence can also be induced by chemotherapeutic reagents in 
tumours (therapy-induced senescence, TIS), particularly in apoptosis-defective contexts 
(Poele et al., 2002; Schmitt et al., 2002; Xue et al., 2007; Gewirtz et al., 2008; Ewald et 
al., 2010; Dörr et al., 2013). Therefore, senescence has been considered as not only an 
intrinsic tumour suppressor but also an alternative therapeutic goal in cancer (Acosta 
and Gil, 2012; Cairney et al., 2012). However, it has been shown that senescence may 
also facilitate tumorigenesis: senescent cells often secrete a wide range of soluble 
factors, which confer a considerable impact on the tumour microenvironment and local 
immune response, providing anti- and/or pro-tumorigenic effects depending on the 
context (Coppé et al., 2010; Pérez-Mancera et al., 2014). 
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Senescence is typically a dynamic and a long-term process, which can involve many 
regulatory effector mechanisms, conferring a diverse and heterogeneous nature to the 
phenotype (Salama et al., 2014). Thus to qualitatively evaluate the senescence 
phenotype, various cellular and biochemical markers have been identified. Senescence 
markers include accumulation of senescence-associated-β-galactosidase (SA-β-gal) 
activity, a persistent DNA damage response, the senescence-associated secretory 
phenotype (SASP) (Kuilman and Peeper, 2009; Coppé et al., 2010), and autophagy 
(Salama et al., 2014). In addition, senescence is typically accompanied by enlarged 
cellular morphology with increased vesicular formation. Nuclei also can show distinct 
morphologic changes, including an enlargement of the nuclei and the nucleoli (Mitsui 
and Schneider, 1976; Bemiller and Lee, 1978), formation of senescence-associated 
heterochromatic foci (SAHF) (Narita et al., 2003; Zhang et al., 2005), up-regulation of 
promyelocytic leukemia (PML) nuclear bodies both in size and number (Ferbeyre et al., 
2000; Pearson et al., 2000; Bischof et al., 2002; 2005), alterations of lamin B1 and other 
components of the nuclear envelope (Maeshima et al., 2006; Barascu et al., 2012; 
Freund et al., 2012; Dreesen et al., 2013; Sadaie et al., 2013; Shah et al., 2013), and 
alteration of nuclear shape (Matsumura et al., 1979) (reviewed in (Goldstein, 1990; 
Cristofalo and Pignolo, 1993)). Hence it has been proposed that it is necessary to 
combine multiple markers, which can be either more common to or unique to different 
contexts, along with the validation of stable exit from the cell cycle, required for the 
phenotype to qualify as senescence (Campisi, 2013; Salama et al., 2014). 
 
AURKB is a member of the aurora family, which also comprises related kinases, 
AURKA and AURKC. Both AURKA and AURKB are ubiquitously expressed but their 
subcellular localization, binding partners, and substrates are highly distinctive. The 
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different isoforms are thus involved in different aspects of cell cycle regulation, whereas 
AURKC is mainly expressed in testis and its function is not well-characterized 
(Gautschi et al., 2008). While AURKA is a centrosomal protein, mainly related to 
centrosome function and bipolar spindle assembly, AURKB, the catalytic component of 
the chromosome passenger complex, plays a key role in correct chromosomal alignment 
and segregation by destabilising erroneous kinetochore-microtubule attachments, and is 
thought to be involved in the spindle assembly checkpoint (SAC). It also has a critical 
role in cytokinesis (Kelly and Funabiki, 2009; Lens et al., 2010; Carmena et al., 2012). 
Inhibition of AURKB in cell culture leads to a failure to bi-orientate chromosomes, 
perturbed cytokinesis and as a consequence, causes polyploidization and an eventual 
loss of viability (Ditchfield et al., 2003; Kaestner et al., 2009; Lens et al., 2010). It was 
recently shown that AURKs inhibitors that are more selective for AURKA induce 
senescence in melanoma cells (Liu et al., 2013). On the other hand, it has also 
previously been shown that the ectopic expression of AURKB in normal HDFs induces 
senescence (Jung et al., 2005). A more recent study, however, reported that AURKB 
overexpression delays senescence and siRNA-mediated AURKB knockdown induces 
senescence in HDFs (Kim et al., 2011). Thus there is room for a more detailed 
characterization of the senescence phenotype caused by the modulation of AURKB 
expression, and more specifically, enzymatic activity. 
 
Due to the diverse nature of senescence, identifying or developing senescence inducing 
factors would not only extend our cancer therapeutic modalities, it would also help in 
elucidating the effector mechanisms of senescence. While numerous genetic 
‘senescence bypass’ screens have been successfully conducted (Jacobs et al., 2000; 
Shvarts et al., 2002; Gil et al., 2004; Acosta et al., 2008; Kortlever et al., 2008; Leal et 
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al., 2008; Rovillain et al., 2011), attempts at ‘senescence inducing’ screens are still 
limited (Ewald et al., 2009; Lahtela et al., 2013). Here, taking advantage of a high 
content fluorescence image analyzing system, we set out simple primary screens for 
small molecules that can induce senescence-related nuclear phenotypes, namely an 
enlargement in nuclear size and SAHF-like chromatin spottiness, in HDFs, followed by 
secondary analyses for detailed senescence validation in both HDFs and tumour cell 
lines. Using a kinase inhibitor library, we identified compounds that induce senescence 
with different nuclear morphologies. Interestingly, although the substrate specificities of 
the kinase inhibitors used were rather limited, a subset of the hit compounds converged 
on AURKB to induce a unique senescence phenotype, where pseudo-G1 tetraploidy or 
polyploidy progressively accumulated. Our study provides a simple and sensitive pro-
senescence screen and the data reinforce the relevance of AURKB as a cancer 
therapeutic target.  
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RESULTS 
Identification of small-molecule compounds that induce senescence-associated 
morphological changes in nuclei 
To establish an image-based screen for senescence inducers, we focused on senescence-
associated nuclear morphological changes as readout using high-throughput fluorescent 
microscopy (Figure 1A). We chose IMR90 human diploid fibroblasts (HDFs), which 
are generally more sensitive to senescence than apoptosis in response to cellular stress, 
and have thus been well-characterized in terms of senescence (Serrano et al., 1997; 
Narita et al., 2003). To optimize the protocol for image acquisition and the analyses of 
nuclear size and nuclear foci (spots), we used normal and HRASG12V-induced senescent 
(RIS) cells, which exhibit prominent senescence-associated heterochromatic foci 
(SAHFs) (Figure 1B) (Narita et al., 2003). Cells were plated on 96-well plates, fixed, 
and stained with DAPI for the automated imaging of nuclei (Supplemental Figure S1, 
Supplemental Table S1). 
 
Using this system we treated normal proliferating IMR90 cells with 160 kinase 
inhibitors (InhibitorSelect, Calbiochem/Merck) and both the nuclear size and the area of 
any subnuclear foci per nucleus were quantified (Figure 1C). The scores from each well 
were normalized to those from the DMSO controls, and the hits were determined by 
setting a threshold of either 1.2-fold (‘relative nuclear average area’) or 3-fold (‘relative 
spot total area per nucleus’) above the control.  11 and 17, out of 160 compounds (tested 
at a standardized 5 µM), scored positive for nuclear size (large) and spottiness (spotty), 
respectively, with a substantial overlap (Figure 1D, Supplemental Table S2). Cells with 
an enlarged or spotty nucleus tended to show a low ‘relative object count per field’, 
which reflected the averaged cell density in the area scanned (Supplemental Figure 
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S1C), suggesting that those hit compounds have an anti-proliferative and/or pro-cell 
death activity. Similar results were obtained when we treated cells with the compounds 
at 3 µM (Supplemental Figure S1D). 
 
We also manually scored all the compounds by visually inspecting the scanned images. 
The nuclei from the cells treated with the 11 ‘size hits’ were all recognized as 
substantially enlarged, and the spotty nuclei in at least 8 of 17 hits-treated cells were 
confirmed by eye. Interestingly, in most of the size hits, the nuclei exhibited a severe 
malformation with a fragmented, cashew nut-like, or doughnut-like morphology, often 
accompanied by multiple micronuclei (‘Type I’), or a milder phenotype (‘Type II’) 
(Figure 1E, Supplemental Figure S1E). The size hits also included nuclei without any 
apparent irregularity (‘Large’). We termed the hit compounds that induced an irregular 
nuclear shape and spotty morphologies IRG and SPT, respectively, and examined 
whether these phenotypes are associated with cellular senescence. 
 
Hit compounds identified by the screen are capable of inducing cellular senescence 
To determine whether the hit compounds induce senescence in IMR90 cells, secondary 
assays were performed for a subset of compounds: those that scored positive as well as 
those that showed a stronger irregular phenotype (Type I) in the screen (Figure 2). To 
optimize the doses of compounds for senescence induction, we tested different 
concentrations of the compounds and chose the doses that did not induce substantial cell 
death (Figure 2A, Supplemental Figure S1F). Cells were exposed to these compounds 
for 4 days (d4), followed by a further incubation without the compounds for 5 days (d9) 
to examine the phenotype irreversibility, a critical feature of senescence.  
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We confirmed that the majority of IRG-treated cells exhibited enlarged and irregular-
shaped nuclei after 4-days treatment, and these nuclear phenotypes were maintained 
after the compounds had been removed (Figure 2A, Supplemental Figure S2).  IRGs 
also induced a stable cell cycle arrest, as determined by a reduction in Cyclin A2, the 
phosphorylation status of RB (Figure 2B), and BrdU incorporation (Figure 2C); even 
after compound removal. Consistently, the number of colony forming cells after two 
weeks’ incubation with compound-free medium was strongly reduced if they were pre-
treated with IRGs (Figure 2D), reinforcing the long-term nature of the observed cell 
cycle arrest. To further confirm that the IRGs induce senescence, we measured 
senescence-associated ß-galactosidase (SA-ß-gal) activity, a hallmark of senescence 
(Dimri et al., 1995). Cells pre-treated with the IRGs typically showed an enlarged 
cellular morphology with increased SA-ß-gal activity (Figure 2E). Although the levels 
of p16, a senescence-associated CDK inhibitor, were unaltered, p53 and its target p21 
(another CDK inhibitor), both of which play important roles in senescence in some 
contexts (Chang et al., 2000; 2002), were stably upregulated in IRG-treated cells 
(Figure 2B). Interestingly, the levels of HMGA2, a senescence marker associated with 
SAHFs (Funayama et al., 2006; Narita et al., 2006), were increased only at the later 
time point. Consistently, SAHF formation was also more evident at d9 (Figure 2F), thus 
senescence is progressively established even during the compound-free period. These 
results suggest that senescence is not an immediate outcome of the treatment, but rather 
a delayed phenotype. These compounds also induced senescence in BJ cells (another 
HDF), although some compounds induced a milder phenotype than in IMR90 cells 
(Supplemental Figure S3).  
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Similarly to IRGs, we also tested selected SPT hits in the secondary senescence assays. 
These compounds were more toxic than the IRGs and we used a lower concentration for 
our validation experiments. At the concentrations used (Figure 3A), the viability of cells 
24h after drug treatment was >90% (Supplemental Figure S1F). Although the nuclear 
phenotype was relatively modest compared to the IRG hits, the formation of DAPI foci 
(morphologically similar to SAHFs) were significantly increased after treatment the 
SPT hit compounds (Figure 3A). In addition, cells pre-treated with these compounds 
were stably arrested, and displayed hallmark features of senescence (Figure 3, B-E).  
Together, our data provide a proof of principle that the nuclear phenotypes can be 
utilized as readout for pro-senescence screens. For the further validation of the 
compounds and nuclear phenotypes in the context of senescence in this study, we 
decided to focus on IRGs and their associated phenotype, which were strong and highly 
distinctive. 
 
IRG compounds induce premature exit from M phase and tetraploidization 
To examine at which cell cycle stage the IRG-treated cells accumulate and become 
senescent, cell cycle profiles as well as the expression pattern of cyclins were analyzed 
by laser scanning cytometer and immunoblotting, respectively. Following treatment 
with IRGs, the number of cells with a 4n DNA content became markedly increased, 
compared to mock-treated cells (Figure 4A). In addition there was a slight increase in 
the number of cells with an 8n DNA content. Interestingly, immunoblot analysis 
showed that those cyclins enriched in G2 or M phase (Cyclin A2 or B1, respectively) 
were decreased whereas a G1 cyclin (Cyclin D1) was increased during IRG-induced 
senescence (Figure 4B). These data suggest that the increased 4n DNA content reflects 
cell cycle arrest in a pseudo-G1 phase after a failed mitosis (i.e. a tetraploid state), 
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rather than G2 arrest. This is highly reminiscent of Aurora kinase B (AURKB) 
inhibitors, which have been shown to induce irregular-shaped nuclear formation with 
polyploidization (Ditchfield et al., 2003; Hauf et al., 2003). Indeed, the IRGs included 
some compounds (Aurora kinase inhibitor II and SU6656) that can inhibit Aurora 
kinases (Bain et al., 2007). Therefore, we tested whether the inhibition of AURKB 
activity by ZM1 (ZM447439) (Girdler et al., 2006), a well-established AURKB 
inhibitor, causes cellular senescence in HDFs. Treatment of both IMR90 and BJ cells 
with ZM1 phenocopied the IRGs effect. Consistent with the previous studies, ZM1 
treatment induced tetraploidy with a highly irregular nuclear shape (Figure 4, A-C). 
Detailed senescence assays confirmed that ZM1-pretreated cells exhibited a stable exit 
from the cell cycle with increased senescence markers (Figure 4C). Similarly to cells 
exposed to IRG compounds, ZM1-treated cells ceased to proliferate by d4, at which 
point they had irregular nuclei and were mostly tetraploid. However, the establishment 
of senescence again appeared to be delayed, steadily developing beyond the 4d 
treatment (Figure 4C, see SAHF count and HMGA2 blotting). Together, these data 
suggest that IRG compounds may induce senescence at least in part through, directly or 
indirectly, inhibiting AURKB activity.  
 
To directly confirm the correlation between irregular nuclei and tetraploidy, the fate of 
mitotic nuclei was tracked by live-cell imaging of cells expressing H2B:EYFP, which 
had been treated with the compounds. As shown in Figure 4D, cells treated with the 
compounds entered M phase and condensed their chromosomes, yet they eventually 
decondensed without proper segregation and formed mostly single and irregular-shaped 
nuclei (Figure 4D, Supplemental Movies S1-S3, and data not shown). These data 
suggest that the irregular-shaped nuclei arise immediately after M phase without proper 
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chromosome segregation and that cell cycle arrest at the G1 tetraploid phase is 
maintained during senescence development in normal HDFs. 
 
Premature exit from M phase without chromosome segregation takes place after 
prolonged mitosis (mitotic slippage) (Gascoigne and Taylor, 2009) or when the spindle 
checkpoint is restrained (Vitale et al., 2011). Inhibition of microtubule dynamics by 
paclitaxel (taxol, a microtubule stabilizing agent) activates the mitotic checkpoint to 
keep cells arrested at the metaphase/anaphase boundary, at which the well-known 
mitosis markers Histone H3 phosphorylated at serine 10 (H3S10ph), a direct substrate 
of AURKB, and Cyclin B accumulate (Figure 4E, lane 2). It has been shown that 
treatment with AURKB inhibitors overrides the paclitaxel-induced SAC (Ditchfield et 
al., 2003; Hauf et al., 2003). To test whether treatment with the IRGs also cancels the 
paclitaxel-induced SAC, we synchronized IMR90 cells with paclitaxel treatment for 12 
hours, and then cells were released into paclitaxel with or without IRGs or ZM1 (Figure 
4E). Similar to ZM1 (Figure 4E, lane 9), the paclitaxel-induced checkpoint was rapidly 
cancelled by the addition of each of the IRGs (Figure 4E, lanes 4-8), while the 
accumulation of Cyclin B1 and H3S10ph was virtually unaffected by the treatment with 
SPTs (lanes 10-12, Supplemental Figure S4). These results further support our 
hypothesis that treatment with the IRGs induces the irregular nuclear phenotype with 
tetraploidization through AURKB inhibition. 
 
It has been shown that AURKB inhibition does not cause a substantial effect on the 
viability of non-proliferating cells (Ditchfield et al., 2003; Hardwicke et al., 2009). To 
ask whether cell cycle progression is required for IRGs to induce senescence, we treated 
quiescent IMR90 cells, induced by serum starvation, with the compounds for 3 days 
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(Supplemental Figure S5A). We then released the compound-treated cells from 
quiescent arrest into compound-free normal medium (10% serum). The pre-treated cells 
(during quiescence) failed to change their nuclear morphology (Supplemental Figure 
S5A, B) and exhibited virtually no reduction in their proliferative capacity 
(Supplemental Figure S5C). Therefore, IRGs and ZM1 induce senescence in 
proliferating, but not in non-proliferating cells. Together, these results suggest that, 
while these compounds have multiple targets, the downstream effects may converge on 
AURKB, which appears to be the dominant pathway for their senescence inducing 
activity. 
 
Specific inhibition of Aurora B kinase activity triggers formation of irregular-
shaped nuclei and cellular senescence 
We next tested whether the IRGs directly inhibit AURKB kinase activity using a 
biochemical kinase profiling assay. Consistent with the phenotypic similarity between 
IRGs and ZM1 treatment, all five IRGs exhibited a substantial inhibitory effect against 
AURKA and AURKB with stronger effects on AURKB, whereas the SPT hits showed 
virtually no effect on the activities of the AURKs (Figure 5A). Although ZM1-induced 
polyploidization has been attributed to AURKB inhibition (Ditchfield et al., 2003; Hauf 
et al., 2003; Girdler et al., 2006), ZM1 also inhibits AURKA, which has both a very 
distinct localization pattern and functions from AURKB, and, in addition to the AURKs, 
IRGs have multiple targets.  
 
To specifically suppress the AURKB activity, we next sought to apply either a stable 
RNAi or dominant negative approach. Using a micro-RNA (miR30) based design (Silva 
et al., 2005), we identified at least two sh-AURKB constructs, which substantially 
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down-regulated the endogenous levels of AURKB and induced comparable phenotypes 
in IMR90 cells when stably transduced (Supplemental Figure S6). We also generated 
retroviral constructs encoding either an EGFP-tagged wild-type or a kinase-dead 
AURKB mutant (AURKBD218N), which has previously been shown to function in a 
dominant-negative fashion (Girdler et al., 2006). Endogenous AURKB levels were also 
down-regulated in cells expressing AURKBD218N or treated with ZM1 (Figure 5B), 
perhaps due to the cell cycle arrest in pseudo G1 phase caused by AURKB inhibition 
(Gully et al., 2012). Immunoblot analysis showed that expression of AURKBD218N or 
sh-AURKB-1, or ZM1 treatment resulted in a reduction in H3S10ph (a substrate of 
AURKB), although cells expressing sh-AURKB-1 exhibited residual AURKB activity 
(Figure 5B). Cyclin A2, Cyclin B1, and phosphorylated RB were down-regulated, 
whereas Cyclin D1 (a G1 cyclin) was increased in AURKBD218N or sh-AURKB-1 
expressing cells, as observed in IRGs/ZM1-treated cells (Figure 5B, also Figure 4B). 
The nuclear phenotype with irregular shape was comparable between AURKBD218N 
expressing cells and ZM1-treated cells, whereas sh-AURKB-1 expressing cells showed a 
milder phenotype (Figure 5C). In addition, the senescence phenotype was also milder in 
the sh-AURKB-1 expressing cells (Figure 5, B-D), implying a negative correlation 
between the AURKB activity and senescence phenotype (see also Supplemental Figure 
S6, A and B). Together, these results indicate that AURKB inhibition-induced 
senescence progressively develops in tetraploid cells with a highly irregular nuclear 
morphology and that it is an immediate consequence of AURKB inhibition in normal 
HDFs.  
 
IRG compounds block the proliferation of cancer cells 
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AURKB inhibition in tumour cells leads to increased polyploidy, and cell cycle arrest or 
cell death depending on the cell type or context (Ditchfield et al., 2003; Hauf et al., 
2003; Gizatullin et al., 2006; Wilkinson et al., 2007; Yang et al., 2007). For example, it 
has been shown that in the presence of AURKB inhibitors, HeLa cervical carcinoma 
cells enter and exit mitosis normally, but fail to divide (Ditchfield et al., 2003; Hauf et 
al., 2003). However, long-term senescence development in tumour cells pre-treated 
with AURK inhibitors remains to be determined. To test whether these compounds 
cause therapy-induced senescence (TIS) in tumour cells, we treated HeLa cells with 
selective IRGs as well as ZM1. We first confirmed that cells were mostly viable (~80% 
at day 9, Supplemental Figure S7A) after treatment with the compounds at the 
concentrations used. Consistent with the phenotype of AURKB inhibition, after a 4-day 
treatment with these compounds the cells contained remarkably enlarged and highly 
irregular/multi-lobulated nuclei, or often they had numerous nuclei per cell (Figure 6A). 
At this stage, the cells showed only a modest retardation of cell cycle progression with 
little sign of senescence (probed through phosphorylation status of RB and BrdU 
incorporation) (Figure 6, B and C). This is perhaps consistent with the previous studies 
suggesting that deficiencies in the p53-p21 pathway enhance the endoreduplication 
caused by aurora kinase inhibitors (Ditchfield et al., 2003; Gizatullin et al., 2006; 
Kaestner et al., 2009). Although HeLa cells express a, functional, wild-type p53, its 
level is down-regulated by human papillomavirus (HPV) E6. After an additional 5-day 
incubation in compound-free medium, however, cells exhibited an accumulation of the 
G1-cyclin (Cyclin D1) and reduced markers of cell cycle progression, such as the S/G2-
cyclin (Cyclin A2), phosphorylated forms of RB, and BrdU incorporation (Figure 6, B 
and C), suggesting that the compound pre-treated cells eventually arrest at a pseudo-G1 
phase. These cells also showed a robust accumulation of SA-ß-Gal activity (Figure 6, D 
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and E). Thus the IRG compounds can induce senescence in HeLa cells. Their long-term 
arrest was confirmed by a colony formation assay in compound-free medium (Figure 
6F). Interestingly, we found up-regulation of the p53-p21 pathway and HMGA2 to be 
delayed (Figure 6B), reinforcing the progressive nature of senescence establishment 
after removal of the compounds.  
 
Since, in HeLa cells, p53 can escape from its E6-mediated down-regulation upon stress 
in some contexts (Wesierska-Gadek et al., 2002), we next asked whether these 
compounds induce senescence in tumour cells that completely lack p53; using H1299, 
the p53-null human lung cancer cell line. While some rounded-up or floating cells were 
observed at both d4 and d9, IRG-treated H1299 cells were largely viable (Supplemental 
Figure S7B). Similarly to HeLa cells, the cells which were attached exhibited highly 
enlarged irregular/lobulated nuclei and/or a multinuclear phenotype (Figure 7A), the 
progressive accumulation of G1-cyclin (Cyclin D1) (Figure 7B), and a significant 
reduction in BrdU incorporation (Figure 7C), suggesting that the IRGs/ZM1 pre-treated 
cells also develop the pseudo-G1 phenotype. Although the reduction in DNA synthesis 
and Cyclin A2 levels was less pronounced than in HeLa cells at d9, the pre-treated 
H1299 cells showed a strong senescence-like phenotype (Figure 7D) with a marked 
reduction in their colony forming capacity, likely due to a combination of senescence 
and cell death (Figure 7E). Altogether our data suggest that AURKB inhibition triggers 
senescence and that this senescence develops whilst the cells are in a tetraploid state or 
in the case of the tumour cells, with reduced or defective p53, a polyploid state. 
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DISCUSSION 
While the primary endpoint of conventional chemotherapy is generally cell death, 
senescence is gaining increasing attention as an alternative goal in cancer therapy 
(Acosta and Gil, 2012; Cairney et al., 2012). Senescence is a heterogeneous and 
collective phenotype mediated by multiple effector programs, which are often 
associated with distinct senescence markers (Salama et al., 2014). Thus this predicts the 
benefit of using diverse markers as a readout in screens for senescence inducers and/or 
senescence bypass.  For example, in our screens for nuclear/chromatin morphological 
alterations, we identified multiple compounds that induce ‘tetraploid senescence’, likely 
through a direct inhibition of AURKB in a progressive manner. Indeed, we observed a 
small increase in the 8n cell population in conventional RAS-induced senescent cells 
(Supplemental Figure S1), suggesting that our screen also allowed the enrichment, or 
‘purification’, of certain sub-types of the senescence phenotype. Although, as a proof of 
principle, we used normal HDFs, which are highly prone to senescence, and a kinase 
inhibitor library with a modest specificity and diversity (160 inhibitors), some of the 
hits were capable of inducing senescence in tumour cell lines. Thus the system is 
potentially applicable to TIS-screening, with a higher throughput and/or different types 
of libraries.  
 
The Aurora kinases are overexpressed in a wide range of human cancers, and they are 
considered as promising therapeutic targets and a number of clinical trials are currently 
at various stages (Keen and Taylor, 2004; Green et al., 2011; Goldenson and Crispino, 
2014). These studies are aimed at inducing cell death and the induction of a senescence-
like response has not been considered in these trials.  
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Inhibition of AURKB, the catalytic component of the chromosome passenger complex, 
overrides the SAC, which thus induces a premature exit from mitosis and interferes with 
cytokinesis, leading to tetraploid/binuclear cells (Keen and Taylor, 2009). However, 
how AURKB inhibition develops into a senescence phenotype in a tetraploid condition 
remains to be elucidated. In addition to an altered SAC, tetraploidization can also be 
induced by mitotic slippage after: a prolonged mitosis, cytokinesis failure, 
endoreduplication, telomere dysfunction, DNA damaging agents, or cell fusion 
(Storchova and Kuffer, 2008; Davoli et al., 2010; Davoli and de Lange, 2011; 
Panopoulos et al., 2014). In addition, it was recently shown that ‘mitotic skip’ is 
involved in tetraploid senescence, particularly induced by DNA damage, where p53 
activation during G2 plays a key role, although any functional relation between 
tetraploidization and senescence was not examined (Johmura et al., 2014; Krenning et 
al., 2014). Tetraploid cells, which possess two sets of homologous chromosomes, are 
suggested to be genetically unstable and have a risk of producing aneuploidy, a 
hallmark of cancer cells (Fujiwara et al., 2005; Ganem et al., 2007; Storchova and 
Kuffer, 2008; Davoli et al., 2010). It is therefore possible that normal diploid cells have 
mechanisms to block the further expansion of tetraploid cells. It was previously 
proposed that there is a p53-dependent G1 ‘tetraploidy checkpoint’, which senses an 
excessive number of chromosomes or centrosomes (Andreassen et al., 2001; Margolis 
et al., 2003), although several subsequent reports have shown that a significant 
population of tetraploid cells can re-enter the cell cycle under optimal culture conditions 
(Uetake and Sluder, 2004; Wong and Stearns, 2005; Hayashi and Karlseder, 2013). 
Thus the existence of the tetraploidy checkpoint has been controversial. Interestingly, 
however, Ganem et al. recently showed that tetraploidization can trigger a ‘G1 arrest’ 
without an apparent DNA damage response, through the activation of the Hippo and 
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p53 pathways (Ganem et al., 2014). It would be very interesting to test whether 
AURKB inhibition-induced senescence is, at least in part, dependent on these pathways.   
 
Our data suggest that senescence is a delayed process rather than an immediate 
consequence of tetraploidization. We also found that the senescence phenotype can still 
progress after AURKB inhibition in p53-defective cells, where cells can undergo 
endoreduplication, leading a highly polyploid senescence (Figures 6 and 7). Thus, 
although extra numbers of chromosomes might contribute to inducing senescence, 
particularly in normal cells, it is also possible that the pathophysiology behind 
polyploidization can provoke senescence effector mechanisms. Indeed, both senescence 
and tetraploidy are associated with some common pathophysiological contexts, 
including wound healing, ageing, and pre-neoplasia (Ermis et al., 1998; Ganem et al., 
2007; Davoli and de Lange, 2011; Gentric et al., 2012). In addition, it was recently 
shown that cell fusion can also induce senescence (Chuprin et al., 2013). In all 
conditions, genotoxic stress or DNA damage response (DDR) is involved in senescence 
(Bartkova et al., 2006; Di Micco et al., 2006; Davoli et al., 2010; Jun and Lau, 2010; 
Chuprin et al., 2013; López-Otín et al., 2013). 
 
While senescence involves diverse effector mechanisms, a persistent DDR is proposed 
to be a widespread mechanism behind senescence induction in diverse types of stress 
(Bartkova et al., 2006; Di Micco et al., 2006; Mallette et al., 2007; d'Adda di Fagagna, 
2008; Rodier et al., 2009). Interestingly, mitotic errors can cause lagging chromosomes, 
leading to formation of micronuclei, which are associated with DNA damage (Guerrero 
et al., 2010; Thompson and Compton, 2011; Crasta et al., 2012). For example, it was 
shown that cells bearing a mutated death inducer obliterator (Dido) gene, which causes 
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SAC dysregulation, show DNA damage localized at their centromeric regions, 
particularly in micronuclei, which are derived via a mitotic defect (Guerrero et al., 
2010). Unlike DNA damage in telomeric regions, which is not readily reparable 
(Fumagalli et al., 2012; Hewitt et al., 2012; Suram et al., 2012) and avoids end 
detection (Carneiro et al., 2010), centromeric DNA damage appears to be reparable 
(Guerrero et al., 2010). However, in addition to telomeric regions, senescence 
associated-persistent DNA damage (collectively called ‘DNA-SCARS’) can also be 
observed within the bodies of chromosomes, although the mechanism for the failed 
DNA repair in these regions remains to be determined (Rodier et al., 2011). It was also 
shown that micronuclei contain aberrant DNA replication-associated DNA damage, 
which can persist during G2, particularly in p53-deficient conditions (Crasta et al., 
2012). We confirmed that the micronuclei caused by IRGs/ZM1 treatment at d4 were 
often positive for both γH2AX (a DNA damage marker) and centromere protein A 
(CENPA) in HDFs (Supplemental Figure S8). Such DNA damage may provoke other 
senescence effectors, contributing to the progressive development of senescence.  
 
It has been proposed that mitotic failure can lead shortly afterwards to a distinct form of 
cell death. This process is called ‘mitotic catastrophe’, but it involves as yet poorly 
understood mechanisms (Vitale et al., 2011; Hayashi and Karlseder, 2013). In addition 
to cell death, senescence has also been implicated in this process (Shay and Roninson, 
2004; Vitale et al., 2011; Hayashi and Karlseder, 2013). For example, factors that 
dysregulate the SAC can also induce senescence, followed by eventual cell death due to 
mitotic catastrophe (Chang et al., 2000; Eom et al., 2005; Yun et al., 2009). In addition, 
HDFs extend their replicative life span when tumour suppressors, including p53, are 
lost and cells escape replicative senescence, eventually undergoing a net growth arrest 
! 22 
with a high rate of cell death (called M2 or ‘crisis’) likely due to mitotic catastrophe 
(Shay and Wright, 2005).  
 
The relationship between senescence ‘escapers’ and mitotic catastrophe raises an 
interesting possibility, a potential mode of selective killing for ‘unstable’ senescent cells. 
Particularly in the TIS context, the incomplete establishment of senescence in tumour 
cells may even promote tumour development and recurrence, in part through the longer-
term aspects of the non-cell-autonomous activities of senescence. Indeed, it has been 
shown that senescence-induction needs to be coupled with the subsequent elimination of 
senescent cells in order to achieve an efficient tumour suppression or pro-senescence 
therapeutic outcome (Xue et al., 2007; Rakhra et al., 2010; Kang et al., 2011). Currently, 
the proposed mechanisms for the ‘selective elimination of senescent cells’ are mainly 
mediated through the immune response (Xue et al., 2007; Krizhanovsky et al., 2008; 
Kang et al., 2011; Pérez-Mancera et al., 2014), while a recent study provided evidence 
that senescent cells can also be eliminated through metabolic perturbation in a TIS 
context (Dörr et al., 2013). Notably the mitotic catastrophe and cell death following 
senescence escape are often associated with deficiencies in the p53-p21 pathway 
(Chang et al., 2000; Shay and Roninson, 2004; Yun et al., 2009), which is often 
abrogated in cancer, thus reinforcing the therapeutic relevance of the pro-senescence 
cancer therapy of using SAC modulators. Consistently, it was recently shown that p53 
deficiency sensitizes cells to the premature mitotic exit caused by AURKB inhibition 
(Marxer et al., 2014). Also, the inhibitor of aurora kinases, VX-680, was previously 
shown to induce cell death preferentially in tumour cells with a compromised p53-
dependent post-mitotic checkpoint, although this effect appears to be highly cell type 
dependent (Gizatullin et al., 2006). The above is also perhaps consistent with our data 
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that p53-null H1299 cells treated with IRGs/ZM1 showed a defective colony forming 
ability with a relatively mild senescence phenotype (Figure 7). While senescence has 
often been suggested to be a ‘back-up’ of apoptotic failure (Schmitt et al, 2002), such 
potential reciprocal back-up interactions between senescence and cell death through 
mitotic catastrophe might provide additional justification for AURKB inhibitors, or 
other SAC modulators, as a therapeutic module in cancer.  
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MATERIALS AND METHODS  
Cell culture and gene transfer 
IMR90 and BJ human fibroblasts (ATCC) were cultured in phenol-red free DMEM 
with 10% FBS under 5% oxygen as described previously (Young et al., 2009). HeLa 
and H1299 cells (ATCC) were cultured in phenol-red free DMEM with 10% FBS. 
Retroviral gene transfer was carried out as described(Narita et al., 2006). RAS-induced 
senescence (RIS) was triggered by the addition of 4OHT to cells expressing H-RASG12V 
fused to the estrogen receptor (ER) ligand-binding domain (ER:RAS)(Young et al., 
2009). Quiescence was induced by incubating cells in DMEM with 0.1% serum for 3 
days. 
 
Plasmids 
The following retroviral plasmids were used: pLNCX2 (ER:H-RASG12V (ER:RAS)) 
(Young et al., 2009), pWZL-hygro (EGFP, EGFP:AURKB, EDFP:AURKBD218N). 
miR30-based shRNA; pMSCV-puro (sh-AURKB) (Silva et al., 2005). The following 
target sequences were used for pMSCV-miR30-AURKB: gaagggatccctaactgtt (#1), 
tttgtttaataaaggctga (#2), ggtccctgtcattcactcg (#3), and actgttcccttatctgtt (#4) 
 
Antibodies  
Antibodies used for Western blotting were as follows: Cyclin A2 (C4710, Sigma), 
Cyclin B1 (4135, Cell Signaling), Cyclin D1 (2926, Cell Signaling), p16 (sc-759, Santa 
cruz), p21 (sc-397, Santa Cruz), p53 (sc-126, Santa Cruz), HMGA2 (sc-30223, Santa 
Cruz), H3S10phos (ab14955, Abcam), Histone H3 (ab1791, Abcam), AURKB (ab2254, 
Abcam), ß-actin (A5441, Sigma), Rb (9309, Cell Signaling). 
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Compound screening 
IMR90 cells were plated in a 96-well plate (353948, BD Falcon) at 10,000 cells per well. 
After 24 hours, the medium was replaced by those containing 3 µM or 5 µM kinase 
inhibitors (InhibitorSelect kinase inhibitor library including 160 compounds, 
Calbiochem/Merck). 4 days after compound addition, cells were washed with PBS, 
fixed in PBS with 4% paraformaldehyde for 15 min, and washed with PBS three times. 
Fixed cells were stained with 1 µg/ml DAPI in PBS (+0.2% Triton X-100) for 5 min. 
Images of the nuclei were captured and analyzed by ArrayScan (Thermo Scientific) 
with the settings shown in Table S1. Briefly, nuclear contour was first determined 
(channel 1) and then spotty structures overlapping with the nuclei were identified 
(channel 2). To rank the compounds by nuclear size and spottiness, the parameters 
‘Relative nuclear average area’ and ‘Relative spot total area per nucleus’ over DMSO 
control were used for the analyses, respectively. The compounds that gave less than a 
count of 100 nuclei per well were categorized as ‘Toxic’ and excluded from analyses. 
Hit compounds from each category were further narrowed down and re-categorized by 
visual inspection. 
 
Compounds 
The final concentrations used for each individual compound was as follows. For HDFs 
and H1299 cells, Aurora kinase inhibitor II: 8 µM (CAS# 331770-21-9; 189404, 
Merck); Cdk2 inhibitor IV, NU6140: 4 µM (CAS# 444723-13-1; 238804, Merck); 
PDGFR tyrosine kinase inhibitor V: 8 µM (CAS# 347155-76-4; 521234, Merck); Rho 
kinase inhibitor IV: 10 µM (555554, Merck or CAS# 913844-45-8; 2485, Tocris); 
SU6656: 10 µM (CAS# 330161-87-0; 572635, Merck); ZM1 (ZM-447439): 2 µM 
(CAS# 331771-20-1; sc-200696, Santa Cruz); EGFR inhibitor: 0.5 µM (CAS# 879127-
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07-8; 324674, Merck); JNK inhibitor IX: 0.5 µM (CAS# 312917-14-9; 420136, Merck); 
MK2a inhibitor: 0.7 µM (CAS# 41179-33-3; 475863, Merck). For HeLa cells, Rho 
kinase inhibitor IV, Cdk2 inhibitor IV and ZM1 were used at the concentration of 1.5, 4 
and 1.5 µM, respectively. Nocodazole: 200 ng/ml (CAS# 31430-18-9; 487928, Merck); 
Paclitaxel: 10 µM (CAS# 33069-62-4; T7402, Sigma).  
 
Senescence and viability assays 
Cells were treated with the hit compounds for 4 days (d4), followed by 5 days 
incubation in compound-free media (d9) unless stated. BrdU incorporation, SA-ß-gal 
and colony formation assays were conducted as described(Narita et al., 2003). Primary 
antibody for BrdU incorporation: 555627, Becton Dickinson. Cell viability was 
determined by trypan blue exclusion. 
 
Immunofluorescence and laser scanning cytometer (LSC) 
Immunofluorescence was performed as described (Narita et al., 2003). Primary 
antibodies: H3K9me3 (07-523, Millipore), H3K36me3 (13C9) (Chandra et al., 2012), 
LMNA (sc-20680, Santa Cruz), α-Tubulin (T5168, Sigma). Images were acquired with 
confocal (when stated) or wide-field fluorescence microscopy. LSC (Compucyte iCys) 
was used to determine cell cycle profile and nuclear size distribution.  
 
Live cell imaging 
IMR90 cells stably expressing Histone H2B:EYFP were synchronized at the G1/S 
border using a double thymidine treatment. Briefly, cells were plated at a density of 
1.76 x 104 cells (in 300 µl medium) per well on to an 8 well µ-slide (80826, ibidi). One 
day after plating, the medium was replaced with that containing 2 mM thymidine and 
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incubated for 14 hours. Cells were washed three times with pre-warmed 200 µl PBS and 
released into thymidine-free medium for 12 hours. Then cells were again incubated 13 
hours in the medium containing thymidine. These synchronized cells were washed three 
times with pre-warmed 200 µl PBS and released into medium containing the 
compounds. 10 hours later, imaging was started and continued for ~5 hours (5 min 
interval) with Eclipse TE2000 PFS Color microscope (Nikon). Conditions for the 
imaging were as follows: x10 objective; three focal planes, 3 µm apart; three fields per 
well; exposure time (bright field: 20 ms; YFP: 400 ms); gain: 13.6x; ND filter: 1. Movie 
and individual files were processed by NIS-Elements software and ImageJ 1.48s. 
 
In vitro kinase assay 
The IC50 of the compounds was identified using a Z’-LYTE in vitro kinase assay and 
was carried out by the SelectScreen biochemical kinase profiling service (Invitrogen). 
The assay was conducted at ten points from 1 nM up to 2 mM with the ATP 
concentration shown: 10 µM for AURKA; 81µM for AURKB.  
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 SUPPLEMENTAL TABLE S1. Optimized ArrayScan settings for detecting nuclear 
morphological changes. 
Category Parameter Setting Comments 
Assay 
Assay algorithm SpotDetector.V3 Name of BioApplication – optimized for spot detection 
Protocol name SAHF_compounds_20x_Spots 
# channels 2 (both DAPI) Allows collection of two images with differing saturation 
Form Factor Falcon 96 well Microplate template 
Image Acquisition 
Objective 20x Highest magnification available to permit detection of distinct puncta 
Acquisition camera mode Standard Pixel resolution 1024x1024; 2x2 binning  
AutoFocus camera mode AutoFocus Pixel resolution 1024x1024; 4x4 binning (faster focusing) 
Scan Limits 
Max Fields for Well 60 Maximum number of images taken per well 
Min Objects for Well 600 Min # of objects (nuclei) to detectfor each well  
Max Sparse Fields for Well 4 # of images taken of ‘Sparse wells’ before moving to next well 
Min Objects for Field 5 ‘Sparse well’ defined as one with <5 nuclei 
Channel 1: Nuclei 
Dye XF100 - Hoechst Name of fluorescence filter  
Exposure Fixed: 40% saturation 
These settings set the threshold for detecting 
nuclei as single objects (i.e. whole nuclei). 
Typical exposure time = 0.054secs. Threshold 
depends on signal intensity. Object identification Fixed Threshold: 20 – 100 
ObjectAreaCh1 Min: 200 Defines min and max size of a nucleus in pixels (eliminates debris and large nuclear clumps) Max: 2500 
ObjectAvgIntenCh1 Min: 0 Rejects very bright objects – most likely debris Max: 2000 
Channel 2: Spots 
Dye XF100 - Hoechst Name of fluorescence filter  
Exposure Fixed: 25% saturation Using a lower saturation helps improve 
sensitivity of spot detection. Typical exposure = 
0.034secs Object identification Fixed Threshold: 20 – 100 
SpotAreaCh2 
Min: 0 
Defines min and max size of spots in pixels 
(improves assay sensitivity by eliminating 
larger areas of nucleus with different DAPI 
intensities) Max: 30 
Assay Parameters 
Use reference wells 1 
Turns on function which allows data to be 
expressed as % responders vs control wells.  
(Responder value set as 2SDs away from 
control) 
SpotDetectRadiusCh2 3 
Determines the size of spots (in pixels) to be 
detected – helps to increase signal:noise by 
eliminating large variances in nuclear staining 
being detected as spots 
SpotSmoothFactorCh2 0 
Turns off smoothing so that only bright spots 
with large contrast cf background are detected 
– improves signal:noise 
RejectBorderObjectsCh1 1 Rejects all nuclei at edge of image 
ObjectSegmentationCh1 0-7 
Splits clumped nuclei into individual objects – 
important for assay sensitivity as SAHF 
phenotype is not 100% penetrant, and nuclear 
area is an important indicator of senescence 
Background CorrectionCh1 35 Improves signal:noise Background CorrectionCh2 10 
 SUPPLEMENTAL TABLE S2. Size hits (nucleus average area) 
Compound name* Primary target kinases* 3 µM 5 µM 
Aminopurvalanol A Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35 II L 
Aurora Kinase Inhibitor II Aurora Kinase   I 
Gö 6976 PKC L   
Herbimycin A, Streptomyces sp. P60v-src L   
JAK3 Inhibitor VI JAK3   I 
Met Kinase Inhibitor met kinase activity   I 
Rho Kinase Inhibitor IV ROCK II I I 
SU9516 Cdk2/A II II 
BAY 11-7082 TNF-α-inducible phosphorylation of IκBα L Toxic 
Cdk2 Inhibitor IV, NU6140 Cdk1/cyclin B I I 
GSK-3 Inhibitor XIII GSK-3 II Toxic 
IC261 CK1δ L   
JAK Inhibitor I murine JAK1 II I 
Kenpaullone Gsk-3β II II 
PDGF RTK Inhibitor PDGFR I I 
SU6656 Src I I 
(Cut-off threshold)   (≥1.2) (≥1.2) 
Hits identified by Arrayscan are highlighted in grey 
I: Irregular (Type I) 
II: Irregular (Type II) 
L: Large 
Toxic: gives count of less than 100 nuclei per well 
* as shown in the Merck Millipore website 
  
 SUPPELMENTAL TABLE S3. Spotty hits (spot total area per nucleus) 
Compound name* Primary target kinases* 3 µM 5 µM 
Aminopurvalanol A Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35   - 
Aurora Kinase Inhibitor II Aurora Kinase   S 
Chelerythrine Chloride PKC S Toxic 
Cdk2 Inhibitor III Cdk2/A, Cdk2/E   S 
EGFR Inhibitor EGFR S S 
GTP-14564 Class III receptor tyrosine kinases   S 
Herbimycin A, Streptomyces sp. P60v-src -   
JAK3 Inhibitor VI JAK3 - - 
MK2a Inhibitor Mk2α S S 
Rho Kinase Inhibitor IV ROCK II S S 
SU9516 Cdk2/A - - 
BAY 11-7082 TNF-α-inducible phosphorylation of IκBα - Toxic 
Cdk2 Inhibitor IV, NU6140 Cdk1/cyclin B - - 
EGFR/ErbB-2/ErbB-4 Inhibitor EGFR/ErbB-2/ErbB-4   S 
GSK-3 Inhibitor XIII GSK-3 - Toxic 
IC261 CK1δ   S 
JAK Inhibitor I murine JAK1   - 
JNK Inhibitor IX JNK2, JNK3 S   
Kenpaullone Gsk-3β   - 
PDGF RTK Inhibitor PDGFR - - 
SB220025 P38MAPK   - 
SU6656 Src - - 
(Cut-off threshold)   (≥2.5) (≥3.0) 
Hits identified by Arrayscan are highlighted in grey 
S: Spotty 
-: Not obvious 
Toxic: gives count of less than 100 nuclei per well 
* as shown in the Merck Millipore website 
 
